- 2025.
- 2024.
- 2023.
- 2022.
- 2021.
- 2020.
- 2019.
- 2018.
- 2017.
- 2016.
- 2015.
- 2014.
- 2013.
- 2012.
- 2011.
- 2010.
- 2009.
- 2008.
- 2007.
- 2006.
- 2005.
- 2004.
- 2003.
- 2002.
- 2001.
- 2000.
- 1999.
- 1998.
- 2025.
- 2024.
- 2023.
- 2022.
- 2021.
- 2020.
- 2019.
- 2018.
- 2017.
- 2016.
- 2015.
- 2014.
- 2013.
- 2012.
- 2011.
- 2010.
- 2009.
- 2008.
- 2007.
- 2006.
- 2005.
- 2004.
- 2003.
- 2002.
- 2001.
- 2000.
- 1999.
- 1998.
2012.
-
- Dec.19.2012
- Phase III Trial of L-BLP25 (Stimuvax®) in Patients with Non-Small Cell Lung Cancer Did not Meet Primary Endpoint(44 KB)
-
- Nov.05.2012
- Announcement on Financial Results for FY2012 2Q
-
- Oct.23.2012
- Ono Enters into Collaboration Agreement with Domain Therapeutics in the Field of GPCR-Based Drug Discovery(57 KB)
-
- Oct.04.2012
- Ono Conducts the Nation's First Microdosing Study Using Its Novel and Innovative Drug Candidate(32 KB)
-
- Sep.03.2012
- Ono and Galapagos Subsidiary BioFocus Sign Drug Discovery Agreement in the Field of CNS Disorders(68 KB)
-
- Aug.02.2012
- Announcement on Financial Results for FY2012 1Q
-
- Jul.23.2012
- Carfilzomib, a proteasome inhibitor, has been granted FDA accelerated approval(101 KB)
-
- Jul.10.2012
- Bristol-Myers K.K. Files for Regulatory Approval in Japan for ORENCIA® Subcutaneous Injection (abatacept [rDNA]), Rheumatoid Arthritis Agent(61 KB)
-
- Jul.02.2012
- Clinical Trial Application submitted for Phase I study of ONO-7268MX1, peptide-cocktail vaccine for hepatocellular carcinoma(14 KB)
-
- Jun.22.2012
- Approval for Additional Indication of "EMEND® Capsule", an Antiemetic Selective Neurokinin-1 (NK1) Receptor Antagonist, for Pediatric Patients Aged 12 and older(23 KB)
-
- Jun.21.2012
- Voting result on carfilzomib at FDA Oncologic Drug Advisory Committee(63 KB)
-
- Jun.08.2012
- Announcement on Appointment of Corporate Officer(42 KB)
-
- Jun.04.2012
- Fully Human Anti-PD-1 Antibody "ONO-4538/BMS-936558" Results from Phase 1 Study in Cancer Patients Published in New England Journal of Medicine (NEJM) and Presented at Annual Meeting of the American Society of Clinical Oncology (ASCO)(288 KB)
-
- May.30.2012
- Ono and Galapagos Subsidiary BioFocus Sign an Additional Target Discovery Agreement in the Field of Allergic Disease(107 KB)
-
- May.15.2012
- Ono Enters into Drug Discovery Collaboration with Scil Proteins for Affilin® Therapeutics(61 KB)
-
- May.14.2012
- Results of PhaseⅡStudy of ONO-2745/CNS 7056, a Short-acting General Anesthetic(20 KB)
-
- May.09.2012
- Announcement on Financial Results for FY2011
-
- Apr.23.2012
- Revisions of Consolidated Financial Forecasts(40 KB)
-
- Apr.17.2012
- ONO-4641 Met Primary Endpoint of Phase II Study in Multiple Sclerosis Patients(20 KB)